Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

GSK starts trial of Nucala to seek alternate indications

Asthma therapy drug to be used to target severe nasal polyposis

- PMLiVE

Delivering ‘accountable marketing’

It’s about time… and data

- PMLiVE

Mobile health and patient outcomes

Putting the humanity back into patient care

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

- PMLiVE

No deal for Stada as private equity takeover bid collapses

65.52% of investors supported the takeover, just shy of the 67.5% needed to close the deal

Digital disruption

How pharma is keeping up with the pace of change

- PMLiVE

ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director

- PMLiVE

Dr Desiree Luthman joins Verona Pharma

She takes up its vice president position

- PMLiVE

Europe delays EMA relocation decision

Will resolve the issue in November, one month later than expected

- PMLiVE

Shoring up the framework

European regulators add a measure of clarity to pharma’s uncertainty around Brexit

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

- PMLiVE

Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links